Anti-interleukin-6 receptor antibody treatment ameliorates postoperative adhesion formation

被引:0
|
作者
Naoki Uyama
Hiroko Tsutsui
Songtao Wu
Koubun Yasuda
Etsuro Hatano
Xian-Yang Qin
Soichi Kojima
Jiro Fujimoto
机构
[1] Hyogo College of Medicine,Department of Surgery
[2] Nishinomiya,Department of Immunology
[3] Hyogo College of Medicine,Liver Cancer Prevention Research Unit
[4] Nishinomiya,undefined
[5] RIKEN Center for Integrative Medical Sciences,undefined
[6] Wako,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Postoperative adhesion formation often ruins the quality of life or is an obstacle to illnesses with curative operation such as cancer. Previously we demonstrated that interferon-γ-promoted fibrin deposition drove postoperative adhesion formation. However, its underlying cellular and molecular mechanisms remain poorly understood. We found that myofibroblasts of the adhesion predominantly expressed signature molecules of mesothelial cells that line the serosa. Microarray analysis revealed IL-6 as a key underlying player, supported by elevated IL-6 levels in the peritoneal fluid of post-laparotomy human subjects. Injured serosa of cecum-cauterized mice also exhibited induction of Il6, which was followed by Tnf, concomitant with rapid accumulation of neutrophils, substantial population of which expressed TGF-β1, a master regulator of fibrosis. Besides, neutrophil-ablated mice showed reduction in induction of the adhesion, suggesting that TGF-β1+neutrophils triggered the adhesion. Human neutrophils expressed TGFB1 in response to TNF-α and TNF in response to IL-6. Moreover, anti-IL-6 receptor monoclonal antibody abrogated neutrophil recruitment and adhesion formation. Thus, IL-6 signaling represents a potential target for the prevention of postoperative adhesions.
引用
收藏
相关论文
共 50 条
  • [31] Uneventful splenectomy and cholecystectomy in a patient treated with anti-interleukin-6 receptor antibody therapy
    Morihiko Ishizaki
    Tetsuro Sasada
    Akane Kunitomi
    Yoshiteru Konaka
    Masato Yagita
    Shutaro Gunji
    Michiyuki Kanai
    Norihiro Nishimoto
    Arimichi Takabayashi
    Langenbeck's Archives of Surgery, 2008, 393 : 423 - 425
  • [32] Possible Role for Tocilizumab, an Anti-Interleukin-6 Receptor Antibody, in Treating Cancer Cachexia
    Ando, Katsutoshi
    Takahashi, Fumiyuki
    Motojima, Shinji
    Nakashima, Kei
    Kaneko, Norihiro
    Hoshi, Kazuei
    Takahashi, Kazuhisa
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : E69 - E72
  • [33] Intracellular Dynamics and Fate of a Humanized Anti-Interleukin-6 Receptor Monoclonal Antibody, Tocilizumab
    Fujimoto, Keiko
    Ida, Hiroaki
    Hirota, Yuko
    Ishigai, Masaki
    Amano, Jun
    Tanaka, Yoshitaka
    MOLECULAR PHARMACOLOGY, 2015, 88 (04) : 660 - 675
  • [34] Safety and efficacy of repetitive treatment with humanized anti-interleukin-6 receptor antibody (MRA) in rheumatoid arthritis (RA).
    Nishimoto, N
    Maeda, K
    Kuritani, T
    Deguchi, H
    Sato, B
    Imai, N
    Kakehi, T
    Suemura, M
    Kishimoto, T
    Yoshizaki, K
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S84 - S84
  • [35] Anti-interleukin-6 receptor antibody for the treatment of remitting seronegative symmetrical synovitis with pitting oedema: a new outlook?
    de Sousa, Rita Noversa
    Rocha, Diana Marques
    Simoes, Marisa Nair
    Rosario, Cristina
    BMJ CASE REPORTS, 2024, 17 (03)
  • [36] Tc-99m-labeled anti-interleukin-6 receptor antibody for in vivo interleukin-6 receptor imaging.
    Sugimoto, K
    Nishimoto, N
    Danno, N
    Kishimoto, T
    Yoshizaki, K
    Arano, Y
    Ono, M
    Saji, H
    Nishimura, T
    JOURNAL OF NUCLEAR MEDICINE, 1998, 39 (05) : 220P - 220P
  • [37] TREATMENT OF SEVERE RHEUMATOID-ARTHRITIS BY ANTI-INTERLEUKIN-6 MONOCLONAL-ANTIBODY
    WENDLING, D
    RACADOT, E
    WIJDENES, J
    JOURNAL OF RHEUMATOLOGY, 1993, 20 (02) : 259 - 262
  • [38] Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
    Sugimoto, K
    Nishimoto, N
    Kishimoto, T
    Yoshizaki, K
    Nishimura, T
    ANNALS OF NUCLEAR MEDICINE, 2005, 19 (04) : 261 - 266
  • [39] Response to Treatment with an Anti-Interleukin-6 Receptor Antibody (Tocilizumab) in a Patient with Hemophagocytic Syndrome Secondary to Immune Checkpoint Inhibitors
    Olivares-Hernandez, Alejandro
    Figuero-Perez, Luis
    Amores Martin, Maria A.
    Bellido Hernandez, Lorena
    Mezquita, Laura
    Vidal Tocino, Maria del Rosario
    Lopez Cadenas, Felix
    Gomez-Caminero Lopez, Felipe
    Escala-Cornejo, Roberto A.
    Cruz Hernandez, Juan Jesus
    CASE REPORTS IN ONCOLOGICAL MEDICINE, 2021, 2021
  • [40] Imaging of lesions in a murine rheumatoid arthritis model with a humanized anti-interleukin-6 receptor antibody
    Kanji Sugimoto
    Norihiro Nishimoto
    Tadamitsu Kishimoto
    Kazuyuki Yoshizaki
    Tsunehiko Nishimura
    Annals of Nuclear Medicine, 2005, 19 : 261 - 266